80 related articles for article (PubMed ID: 24496747)
1. Investigating DNA methylation as a mediator of genetic risk in childhood acute lymphoblastic leukemia.
Xu K; Li S; Pandey P; Kang AY; Morimoto LM; Mancuso N; Ma X; Metayer C; Wiemels JL; de Smith AJ
Hum Mol Genet; 2022 Oct; 31(21):3741-3756. PubMed ID: 35717575
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics of acute lymphocytic leukemia.
Garcia-Manero G; Yang H; Kuang SQ; O'Brien S; Thomas D; Kantarjian H
Semin Hematol; 2009 Jan; 46(1):24-32. PubMed ID: 19100365
[TBL] [Abstract][Full Text] [Related]
3. Converging genetic and epigenetic drivers of paediatric acute lymphoblastic leukaemia identified by an information-theoretic analysis.
Koldobskiy MA; Jenkinson G; Abante J; Rodriguez DiBlasi VA; Zhou W; Pujadas E; Idrizi A; Tryggvadottir R; Callahan C; Bonifant CL; Rabin KR; Brown PA; Ji H; Goutsias J; Feinberg AP
Nat Biomed Eng; 2021 Apr; 5(4):360-376. PubMed ID: 33859388
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation as a potential mediator of environmental risks in the development of childhood acute lymphoblastic leukemia.
Timms JA; Relton CL; Rankin J; Strathdee G; McKay JA
Epigenomics; 2016 Apr; 8(4):519-36. PubMed ID: 27035209
[TBL] [Abstract][Full Text] [Related]
5. Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia.
Ryba T; Battaglia D; Chang BH; Shirley JW; Buckley Q; Pope BD; Devidas M; Druker BJ; Gilbert DM
Genome Res; 2012 Oct; 22(10):1833-44. PubMed ID: 22628462
[TBL] [Abstract][Full Text] [Related]
6. Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting.
Knight T; Irving JA
Front Oncol; 2014; 4():160. PubMed ID: 25009801
[TBL] [Abstract][Full Text] [Related]
7. Increased MYB alternative promoter usage is associated with relapse in acute lymphoblastic leukemia.
Fehr A; Arvidsson G; Nordlund J; Lönnerholm G; Stenman G; Andersson MK
Genes Chromosomes Cancer; 2023 Oct; 62(10):597-606. PubMed ID: 37218648
[TBL] [Abstract][Full Text] [Related]
8. Genetic Factors and Long-term Treatment-Related Neurocognitive Deficits, Anxiety, and Depression in Childhood Leukemia Survivors: An Exome-Wide Association Study.
Petrykey K; Lippé S; Sultan S; Robaey P; Drouin S; Affret-Bertout L; Beaulieu P; St-Onge P; Baedke JL; Yasui Y; Hudson MM; Laverdière C; Sinnett D; Krajinovic M
Cancer Epidemiol Biomarkers Prev; 2024 Feb; 33(2):234-243. PubMed ID: 38051303
[TBL] [Abstract][Full Text] [Related]
9. Protein tyrosine phosphatase receptor type γ is a JAK phosphatase and negatively regulates leukocyte integrin activation.
Mirenda M; Toffali L; Montresor A; Scardoni G; Sorio C; Laudanna C
J Immunol; 2015 Mar; 194(5):2168-79. PubMed ID: 25624455
[TBL] [Abstract][Full Text] [Related]
10. The Role of the Tumor Suppressor Gene Protein Tyrosine Phosphatase Gamma in Cancer.
Boni C; Sorio C
Front Cell Dev Biol; 2021; 9():768969. PubMed ID: 35071225
[TBL] [Abstract][Full Text] [Related]
11. Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.
Ismail MA; Samara M; Al Sayab A; Alsharshani M; Yassin MA; Varadharaj G; Vezzalini M; Tomasello L; Monne M; Morsi H; Qoronfleh MW; Zayed H; Cook R; Sorio C; Modjtahedi H; Al-Dewik NI
Mol Genet Genomic Med; 2020 Oct; 8(10):e1319. PubMed ID: 32700424
[TBL] [Abstract][Full Text] [Related]
12. Transcription Factor RREB1: from Target Genes towards Biological Functions.
Deng YN; Xia Z; Zhang P; Ejaz S; Liang S
Int J Biol Sci; 2020; 16(8):1463-1473. PubMed ID: 32210733
[TBL] [Abstract][Full Text] [Related]
13. PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.
Drube J; Ernst T; Pfirrmann M; Albert BV; Drube S; Reich D; Kresinsky A; Halfter K; Sorio C; Fabisch C; Hochhaus A; Böhmer FD
Oncotarget; 2018 Feb; 9(10):9442-9455. PubMed ID: 29507701
[TBL] [Abstract][Full Text] [Related]
14. A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients.
Vezzalini M; Mafficini A; Tomasello L; Lorenzetto E; Moratti E; Fiorini Z; Holyoake TL; Pellicano F; Krampera M; Tecchio C; Yassin M; Al-Dewik N; Ismail MA; Al Sayab A; Monne M; Sorio C
J Hematol Oncol; 2017 Jun; 10(1):129. PubMed ID: 28637510
[TBL] [Abstract][Full Text] [Related]
15. A functional polymorphism in the CEBPE gene promoter influences acute lymphoblastic leukemia risk through interaction with the hematopoietic transcription factor Ikaros.
Wiemels JL; de Smith AJ; Xiao J; Lee ST; Muench MO; Fomin ME; Zhou M; Hansen HM; Termuhlen A; Metayer C; Walsh KM
Leukemia; 2016 May; 30(5):1194-7. PubMed ID: 26437776
[No Abstract] [Full Text] [Related]
16. Receptor-type protein tyrosine phosphatases in cancer.
Du Y; Grandis JR
Chin J Cancer; 2015 Feb; 34(2):61-9. PubMed ID: 25322863
[TBL] [Abstract][Full Text] [Related]
17. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
Irving J; Matheson E; Minto L; Blair H; Case M; Halsey C; Swidenbank I; Ponthan F; Kirschner-Schwabe R; Groeneveld-Krentz S; Hof J; Allan J; Harrison C; Vormoor J; von Stackelberg A; Eckert C
Blood; 2014 Nov; 124(23):3420-30. PubMed ID: 25253770
[TBL] [Abstract][Full Text] [Related]
18. PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia.
Xiao J; Lee ST; Xiao Y; Ma X; Houseman EA; Hsu LI; Roy R; Wrensch M; de Smith AJ; Chokkalingam A; Buffler P; Wiencke JK; Wiemels JL
Int J Cancer; 2014 Sep; 135(5):1101-9. PubMed ID: 24496747
[TBL] [Abstract][Full Text] [Related]
19. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
